Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Asieris Pharma Doses First Patient in China Bladder Cancer Trial

publication date: Mar 31, 2017
Asieris Pharma, a China oncology pharma, has dosed the first bladder cancer patient in a pivotal Phase III trial of APL-1202, its lead candidate. Asieris aims to repurpose existing drugs while it develops novel, improved candidates for the same target. APL-1202, an oral inhibitor of MetAP2, is a wide spectrum antibiotic that has been in use for 50 years and is now known to have an anti-angiogenesis effect. Asieris is headquartered in Taizhou's China Medical City and has its clinical trial office in Shanghai. More details...

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital